---
layout: default
title: VisuEvoÂ® vs CationormÂ® â€“ Full Study Summary (Fogagnolo et al. 2020) ğŸ“ŠğŸ’§
permalink: /clinical/visuevo-vs-cationorm-2020/
---

# VisuEvoÂ® vs CationormÂ® Head-to-Head Trial  
**Full Evidence Summary â€“ Fogagnolo et al. 2020**  

**Quick Summary for Busy HCPs** (2â€“3 min read) â­  
Multicenter, double-blind, randomized cross-over (12 weeks, no washout). N=72 DED patients (54 EDE/MGD-related, 18 NEDE/preservative-induced).  

- **Primary (TBUT)**: Baseline 3.2 s â†’ +1.3 s at week 2 â†’ ~5.4â€“6.0 s at week 6 (p<0.001 both arms).  
- **Non-inferiority** of VisuEvoÂ® (VSE) to CationormÂ® (CTN): Confirmed (95% CI -1.19 to +0.05 > -0.5 s margin; p>0.10 all visits).  
- **OSDI symptoms**: 37 (severe) â†’ 19 (mild) (~18-point drop, p<0.001).  
- **Osmolarity**: 314 â†’ ~305â€“307 mOsm/L (normalized).  
- **Anti-inflammatory/lipid win** (subgroup tears): Cytokines (IFN significant p<0.05) & lipids (sphingosine, S1P p<0.05) reduced â€“ aligns with VSE's Omega-3 (DHA/EPA) + Vit D3 resolving action!  
- **Other**: Staining ~15% better, incomplete blinks â†“ (p<0.001), no major Schirmer change.  
- **Safety**: Excellent â€“ transient blur similar (11 CTN-only, 10 VSE-only, 16 both).  

**Bottom line**: VSE non-inferior to CTN in restoring tear film, stability, surface health, and reducing inflammation in **both EDE & NEDE**. Strong lipid option for your patients! ğŸ‘€ğŸ’ª  

**Full Open-Access Paper**: [PMC7308118 â€“ Click to read complete article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7308118/)  

*Educational material for healthcare professionals. Paraphrased/cited from original. Not promotional. Consult full text & product labeling.*

----------------------------------------------------------------------------------------------------

**Study Design & Patients**  
- Multicenter, double-blind, randomized, prospective cross-over (NCT03833882).  
- 72 patients: Age 65Â±17 y, 73% female; EDE n=54 (MGD/hormonal/high evaporation), NEDE n=18 (BAK-preserved glaucoma â‰¥2 years, abnormal Ferning).  
- Inclusion: TBUT <7 s, OSDI â‰¥13, Schirmer >10 mm + specific subtypes (Box 1).  
- Treatment: 1 drop TID Ã—6 weeks each (random sequence).  
- Visits: Screening â†’ Baseline â†’ Week 2/6 each period.  
- Primary: TBUT change. Non-inferiority margin -0.5 s.  

**Figure 1 â€“ Study Flow**  
![Study Flow Diagram](https://pmc.ncbi.nlm.nih.gov/articles/PMC7308118/bin/OPTH-14-1651-g0001.jpg)  
*Cross-over without washout â€“ randomization at baseline, switch at week 6.*

----------------------------------------------------------------------------------------------------

**Main Results â€“ Whole Population (N=63 efficacy)**  
Both products showed significant improvements vs baseline (p<0.001 key endpoints). No inter-group differences (p>0.10).

**Table 1 â€“ Primary & Secondary Endpoints**

| Endpoint                  | Baseline       | Intermediate (VSE/CTN) | Final (VSE/CTN)       | p (VSE vs CTN) |
|---------------------------|----------------|-------------------------|-----------------------|----------------|
| TBUT (s)                  | 3.2 Â± 1.5     | 4.5 Â± 1.9 / 4.5 Â± 1.9  | 5.4 Â± 2.4 / 6.0 Â± 3.1 | 0.10 / 0.63   |
| OSDI Score                | 37 Â± 12       | 23 Â± 15 / 23 Â± 15      | 19 Â± 13 / 19 Â± 14     | 0.43 / 0.44   |
| Osmolarity (mOsm/L)       | 314 Â± 23      | 305 Â± 16 / 305 Â± 16    | 305 Â± 15 / 307 Â± 20   | 0.46 / 0.60   |
| Incomplete Blinks (N/min) | 7 Â± 5         | 5 Â± 5 / 5 Â± 5          | 4 Â± 4 / 2 Â± 2         | 0.35 / 0.0004 |
| Fluorescein Staining      | Baseline      | ~15% improvement       | Stable                | No diff       |

- TBUT: Non-inferiority achieved (estimated effect -0.57 s, 95% CI -1.19 to 0.05).  
- Blinks: Incomplete â†“ significantly (p<0.001 overall).  

**Figure 2 â€“ Bland-Altman Plot (TBUT)**  
![Bland-Altman Plot](https://pmc.ncbi.nlm.nih.gov/articles/PMC7308118/bin/OPTH-14-1651-g0002.jpg)  
*Points cluster near zero â€“ confirms similar performance between VSE & CTN.*

----------------------------------------------------------------------------------------------------

**Anti-Inflammatory & Lipid Results â€“ Table 2** (Tear subgroup ~20 patients)  
All reduced during treatment (no VSE-CTN differences). Significant for IFN, sphingosine, S1P (p 0.06â€“<0.0014 whole population). Ties to VSE's Omega-3/Vit D3 for resolving inflammation!

| Parameter                          | TOTAL Baseline | TOTAL Final     | Notes (significance) |
|------------------------------------|----------------|-----------------|----------------------|
| IL-6 (pg/mL)                       | 12.62 Â± 14.67 | 8.15 Â± 11.26   | Reduced              |
| IL-8 (pg/mL)                       | 623.7 Â± 719.6 | 502.5 Â± 1266.0 | Reduced              |
| IFN (pg/mL)                        | 2.81 Â± 2.09   | 1.69 Â± 1.97*   | Significant (p<0.05) |
| Ceramides (pmol/mg)                | 181 Â± 248     | 100 Â± 106      | Reduced              |
| Sphingomyelin (pmol/mg)            | 596 Â± 653     | 379 Â± 378      | Reduced              |
| Sphingosine (pmol/mg)              | 537 Â± 435     | 179 Â± 135*     | Significant (p<0.05) |
| Sphingosine 1-phosphate (pmol/mg)  | 4 Â± 2         | 2 Â± 1*         | Significant (p<0.05) |

*Significant vs baseline.

----------------------------------------------------------------------------------------------------

**Subgroups & Safety**  
- **EDE/NEDE**: Similar improvements; NEDE slightly worse baseline TBUT, VSE numerically better osmolarity (299 vs 318 mOsm/L, p=0.10). Blinks patterns differed (EDE more complete baseline; NEDE dramatic incomplete reduction).  
- **Safety**: Excellent. Transient blurred vision: CTN only 11, VSE only 10, both 16. No serious AEs.

**STAR TAKEAWAY**  
VisuEvoÂ® proven **non-inferior** to CationormÂ® across all parameters â€“ with meaningful tear inflammation/lipid reductions that complement its Omega-3 + Vit D3 formula for resolving dry eye fire! ğŸ”¥ğŸ’§

[Back to Clinical Evidence Hub](/clinical/) | [Back to SGBioPharma ğŸ‘€](/sgbiopharma/) | [Home ğŸ ](/)

<!-- Build trigger - added Jan 27 2026 -->
